Skip to content
The GLP-1 Verdict
Menu

Evidence review

GLP-1 Drug Interactions: What Actually Interacts With Semaglutide and Tirzepatide

Semaglutide and tirzepatide slow digestion, which is the mechanism behind their real drug interactions — birth control pills, insulin, and narrow-window drugs.

By The Verdict Desk, Provider Review Board
On this page

The Verdict's #1 pick

CoreAge Rx

Grade A

The most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.

See the verdict
Semaglutide
$149/mo
Tirzepatide
$349/mo
Coverage
All 50 states
Access
Compounded

Advertising disclosure · we may earn a commission at no extra cost to you. It never changes what we write about a product or its Verdict Score.

Also ranked

Sesame Care

Grade B+

An established national telehealth marketplace carrying real brand-name GLP-1s — Wegovy (pen and pill), Zepbound, Ozempic and Mounjaro — where most programmes we rank carry none, plus provider-by-provider price transparency.

Visit Sesame Care

Semaglutide and tirzepatide do not interact with other drugs the way, say, grapefruit juice interacts with statins — there is no shared liver enzyme pathway driving most of the concern. The real mechanism is simpler and more mechanical: both drugs slow gastric emptying, which changes how fast anything else you swallow gets absorbed3. That one fact explains almost every interaction worth knowing about.

Oral hormonal contraceptives — the one with an explicit label instruction

This is the interaction with the clearest, most actionable guidance. Zepbound's FDA label instructs: "Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation"1. The concern is delayed gastric emptying reducing how consistently an oral pill is absorbed — not a hormonal interaction, but a timing one. Non-oral hormonal contraceptives (the patch, ring, injection, IUD) are not affected1. A 2025 pharmacokinetics review of approved GLP-1 and GLP-1/GIP drugs backs this up as a class-relevant absorption issue, not a tirzepatide-only quirk4. If you are on the pill and starting or increasing a GLP-1 dose, this is the single most important line item to raise with your prescriber.

Insulin and sulfonylureas — hypoglycemia risk

Both Wegovy and Zepbound lower blood glucose, and when combined with insulin or an insulin secretagogue (the drug class that includes sulfonylureas like glipizide or glimepiride), the risk of hypoglycemia rises1. This matters most for anyone using a GLP-1 alongside diabetes medication, and it is the reason a real prescriber reviewing your full medication list — not a rubber-stamp intake form — is one of the checks in our provider checklist. If you are on insulin or a sulfonylurea, expect your provider to discuss a dose adjustment, not just add a GLP-1 on top.

Narrow-therapeutic-index oral drugs — warfarin and levothyroxine are the named examples

Because absorption timing shifts, both labels specifically flag oral medications "dependent on threshold concentrations for efficacy" and those "with a narrow therapeutic index (e.g., warfarin)" for closer monitoring when taken alongside a GLP-11. Warfarin is named explicitly because small absorption changes can meaningfully shift its blood-thinning effect. Levothyroxine (thyroid hormone replacement) is another concrete data point: in a drug-interaction study with the semaglutide tablet, levothyroxine exposure increased by 33%2 — not dangerous on its own, but exactly the kind of shift that warrants a follow-up thyroid panel rather than assuming nothing changed.

Alcohol — not a labeled interaction, but a real overlap in effect

Neither the Wegovy nor Zepbound label lists a specific alcohol interaction warning. That is worth saying plainly rather than inventing a false-precision answer. What is true is that both alcohol and GLP-1s can independently cause nausea and slow digestion, so the two effects can compound — people commonly report feeling worse combining the two than either alone. Treat this as a tolerability issue to discuss with your prescriber, not a labeled drug interaction with a defined mechanism.

The bottom line: this is a "tell your provider everything" drug class, not a "avoid this list" one

Unlike drugs with a short list of absolute contraindicated combinations, GLP-1s mostly interact by degree — slower absorption of whatever else you take by mouth, amplified diabetes-medication effects, and a specific, actionable four-week contraception workaround. None of this is a reason to avoid the medication; it is a reason to give a prescriber your complete medication list before starting, and to make sure the provider you choose actually reviews it. That is exactly the verification and prescriber-access standard our Verdict Score methodology scores every provider against — see the ranked reviews for who does it well.

This is editorial information, not medical advice. Confirm your specific medications and interaction risk with a licensed clinician or pharmacist before starting a GLP-1.

Frequently asked questions

Does tirzepatide affect birth control pills?

The Zepbound label specifically instructs patients on oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after starting and for 4 weeks after each dose increase, because delayed gastric emptying can reduce oral-pill absorption. Non-oral hormonal contraceptives are not affected.

Can I take a GLP-1 with insulin?

Many people do, under medical supervision, but combining a GLP-1 with insulin or a sulfonylurea raises the risk of hypoglycemia (low blood sugar). Expect your provider to review and possibly adjust your diabetes medication dose.

Does semaglutide interact with thyroid medication?

A drug-interaction study with the semaglutide tablet found levothyroxine exposure increased by 33%. It is not a reason to avoid the combination, but it is a reason to have thyroid levels monitored after starting.

References

The 4 sources below are cited in full, and this guide sits alongside the rest of our evidence library, where every claim about the medicine traces to a trial, a label or the regulatory record.

  1. U.S. Food and Drug Administration (2023). Zepbound (tirzepatide) injection — Drugs@FDA prescribing information. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806
  2. U.S. Food and Drug Administration (2021). Wegovy (semaglutide) injection — Drugs@FDA prescribing information. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256
  3. U.S. Food and Drug Administration (2021). Wegovy (semaglutide) injection — Drugs@FDA prescribing information. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256
  4. Min JS, Jo SJ, Lee S, et al. (2025). A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist. Drug Design, Development and Therapy. https://pubmed.ncbi.nlm.nih.gov/40330819/

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.